ClinicalTrials.gg
CompletedNCT04531475Updated Jul 17, 2025

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

A Phase 2 interventional study of X842 and X842 Placebo in Reflux Esophagitis, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Completed at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Jiangsu Sinorda Biomedicine Co., Ltd · Phase 2, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2020, registered Aug 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Esophagitis, Peptic with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Esophagitis, Peptic · China.

Enrollment
8th of 15
90 · median 90
Started
2020
with 2 others
Phase 2
2 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
3 of 18
Jiangsu Sinorda Biomedicine Co., Ltd

Among the 18 studies in Esophagitis, Peptic with a site in China, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 in phase 2, and was the 4th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

8 of the 18 studies in Esophagitis, Peptic with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Esophagitis, Peptic with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

Read the detailed description

It is designed as a multicenter, randomized, double-blind, double-simulation, high and low dose group, active comparator-controlled, parallel-group study to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

03

Conditions studied

  • Reflux Esophagitis

Keywords

  • X842
  • Reflux Esophagitis
  • GERD
  • PCAB
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, 18 years ≤ age ≤ 75 years;
  2. Within 14 days prior to randomization, the subjects are endoscopically diagnosed with reflux esophagitis from Los Angeles (LA) grade A to D (notes: the percent of the subjects with LA grade A of RE should be no more than 60% of the all subjects who are planned to be enrolled in the study);
  3. Subjects fully understand the trial contents, participate in the trial voluntarily, and sign the forms.

Exclusion criteria

Exclusion criteria:

  1. Subjects who receive X842 capsules or other P-CAB drugs in previous clinical studies;
  2. Subjects known to be allergic to X842 capsules or lansoprazole enteric-coated capsules, or relevant of X842 capsules or lansoprazole enteric-coated capsules, such as lactose, microcrystalline cellulose, croscarmellose sodium, sodium dodecyl sulfate, sodium stearyl fumarate, and silicon dioxide;
  3. Subjects unable to receive upper gastrointestinal endoscopy;
  4. Subjects unable to independently complete the subject diary cards;
  5. Subjects known to have any concomitant disease that may affect the esophagus (eosinophilic esophagitis, esophageal varices, dermatosclerosis, viral or fungal infectious esophagitis, or esophageal stenosis), or have a history of esophageal radiotherapy or cryotherapy (but subjects are eligible for this study if they have concomitant esophageal hiatal hernia)
  6. Subjects known to have a history of Barrett's esophagus, or who have Barrett's esophagus discovered during endoscopy at screening;
  7. Subjects who have acute upper gastrointestinal hemorrhage within 4 weeks prior to enrollment;
  8. Subjects with active peptic ulcer discovered during upper gastrointestinal endoscopy, or subjects with suspicious or definite ;
  9. Subjects known to have Zollinger-Ellison syndrome or inflammatory bowel disease (IBD);
  10. Subjects with concomitant cholecystolithiasis, gallbladder wall crystal or gallbladder polyp discovered by B ultrasonography at screening;
  11. Subjects with a history of surgery that may affect the esophagus (for example, fundoplication and mechanical distension for esophageal stenosis), or subjects with a history of cholecystectmy or surgery of stomach or duodenum (except endoscopic excision of benign polyps, and except simple suture surgeries such as for gastric perforation);
  12. Subjects with a history of malignancies within 5 years prior to screening (a subject can participate in the study if his /her skin basal cell carcinoma or carcinoma in situ of uterine cervix has been cured);
  13. Subjects with concomitant serious diseases of central nervous system, cardiovascular system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system, or hematological system, and the investigator thinks these diseases may mix the study results up or affect the safety of the subject;
  14. Laboratory test results at screening showing that or AST is larger than 1.5 times of the , or kidney function index Cr is larger than the upper limit of normal (a re-examination is permitted in the study, and subjects will be excluded if they still fail to meet the inclusion criteria);
  15. Subjects who use proton pump inhibitors (PPIs), P-CABs, histamine2 receptor antagonists (H2RAs), or gastric mucosal protectors (except hydrotalcite) within 2 weeks prior to randomization;
  16. Subjects who chronically use (>12 doses / month) non-steroidal anti-inflammatory drug (including cyclooxygenase-2 inhibitor), anti- drug (such as aspirin and clopidogrel), or anticoagulant (such as Warfarin) prior to randomization, and can not stop the medication during the trial;
  17. At screening, subjects with abnormalities, including serious arrhythmia, multifocal preventricular contraction (PVC), grade II or above atrioventricular block, and prolongation of the Q-T interval (≥450 ms in males and QTc≥470 ms in females);
  18. Diabetic subjects with poorly controlled blood glucose level (fasting blood glucose (FBG) > 10.0 mmol/L), or hypertensive subjects with poorly controlled blood pressure (systolic pressure ≥150 mmHg or diastolic pressure ≥100 mmHg);
  19. Subjects with known acquired immunodeficiency syndrome (AIDS);
  20. Subjects who are using atazanavir sulfate or ripivirin hydrochloride at screening;
  21. Subjects with a history of long-term abuse of drug or alcohol within 6 months prior to screening;
  22. Female subjects with suspicious or known pregnancy, those in breast-feeding period, or those who are planned to become pregnant during the trial. At the investigator's discretion, women of childbearing age who cannot use a medically-proven and reliable method of from signing the forms to 4 weeks after the last dose of the study;
  23. Subject who plan to have a surgery requiring hospitalization, or subject who need to have a surgery during his/her participation in the study;
  24. Subjects who participate in other drug/medical device clinical studies and use the drug/medical device within 3 months prior to randomization;
  25. Subjects who are considered unsuitable for participating in this trial by investigators.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    X842 50 mg QD

    X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.

    Drug: X842 · Drug: Lansoprazole Placebo

  • Experimental
    X842 100 mg QD

    X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.

    Drug: X842 · Drug: Lansoprazole Placebo

  • Experimental
    Lansoprazole 30 mg QD

    Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.

    Drug: X842 Placebo · Drug: Lansoprazole

Interventions

  • DrugX842

    X842 capsules

    Also known as: Undecided

  • DrugX842 Placebo

    X842 placebo-matching capsules

    Also known as: Undecided

  • Lansoprazole capsules

    Also known as: Undecided

  • DrugLansoprazole Placebo

    Lansoprazole placebo-matching capsules

    Also known as: Undecided

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Whose Reflux Esophagitis is Cured as Confirmed by Endoscopy at Week 4 of Treatment

    Subjects cured of RE are defined as subjects who are endoscopically confirmed to be cured of RE.

    Time frame: 4 weeks

Secondary outcomes

  1. Proportion of Subjects Whose Reflux Esophagitis LA Grade is Decreased by ≥1 as Confirmed by Endoscopy at Week 4 of Treatment

    The endoscopic results must describe RE severity according to the LA grading criteria.

    Time frame: 4 weeks

  2. Changes in Gerd-Q Score at Week 2 and 4 Compared With the Baseline

    Subjects must record RE symptoms that occur within 7d prior to each visit in the Gerd-Q under the guidance of the investigator.

    Time frame: Week 2 and Week 4

  3. Changes in Serum Gastrin at Week 2 and 4 of Treatment Compared with the Baseline

    Serum gastrin testing will be conducted at the central laboratory. The change between the serum gastrin values collected at Weeks 2 and 4 relative to baseline.

    Time frame: Week 2 and Week 4

  4. Measurement of the PK Profile

    Plasma concentrations of X842 and its metabolites are measured to determine X842 exposure in patients.

    Time frame: Week 2 and Week 4

  5. Number of Subjects Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)

    Adverse event is defined as any adverse medical event that is observed in a subject who is receiving a drug treatment or in a clinical study, and that does not necessarily have a causal relationship with the treatment.

    Time frame: Up to 6 weeks

  6. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood serum

    Number of subjects with any markedly abnormal values in laboratory tests of blood serum collected throughout study is reported.

    Time frame: Up to 6 weeks

  7. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood

    Number of subjects with any markedly abnormal values in laboratory tests of blood collected throughout study is reported.

    Time frame: Up to 6 weeks

  8. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of urine

    Number of subjects with any markedly abnormal values in laboratory tests of urine collected throughout study is reported.collected throughout study is reported.

    Time frame: Up to 6 weeks

  9. Number of Subjects With Markedly Abnormal Electrocardiogram (ECG) Findings

    The investigator or the sub-investigator interpreted the ECG using one of the following categories: "within normal limits", "abnormal but not clinically significant", or "abnormal and clinically significant".

    Time frame: Up to 6 weeks

  10. Vital signs of body temperature

    °C = degrees Celsius

    Time frame: Up to 6 weeks

  11. Vital signs of blood pressure

    Blood pressure measurements included systolic (mmHg) and diastolic (mmHg).

    Time frame: Up to 6 weeks

07

Study locations

16 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Liuan People's Hospital
    Liu‘an, Anhui 237016, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • The Affiliated Hospital of Guzihou Medical University
    Guiyang, Guizhou 550004, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • Affiliated Hospital of Xiangnan University
    Chenzhou, Hunan 423000, China
  • The First people's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • Jiangxi PingXiang People's Hospital
    Pingxiang, Jiangxi 337000, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong 256600, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Tongji Hospital of Tongji University
    Shanghai, Shanghai Municipality 250065, China
  • The Second Affiliated Hospital of Chongqi Medical University
    Chongqing, Sichuan 400010, China
  • Taizhou Municipal Hospital
    Taizhou, Zhejiang 318000, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, 101100, China
08

References and documents

Publications

  • Zhu S, Han M, Zong Y, Meng F, Liu Q, Tuo B, Zhang Z, Wang Q, Liu X, He S, Zhen Y, Shao D, Wang S, Xu B, Li X, Tang H, Miu Y, Liu C, Hu J, Hu P, Xiu J, Lu M, Wu Y, Zhang S. A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis. Clin Transl Gastroenterol. 2025 Apr 1;16(4):e00803. doi: 10.14309/ctg.0000000000000803. PubMed 39836012 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Oct 2020, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Aug 28, 2020
StartActual
Jan 21, 2020
Primary completionActual
Oct 24, 2020
CompletionActual
Jan 12, 2021
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04531475
Lead sponsor
Jiangsu Sinorda Biomedicine Co., Ltd
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Jan 21, 2020
Primary completion
Oct 24, 2020
Completion
Jan 12, 2021
Last update
Jul 17, 2025

Study contacts

Pingsheng Hu, Ph.D
study chair · Jiangsu Sinorda Biomedicine Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linaprazan glurate · Lansoprazole

Start the discussion